Monotherapy for patients with metastatic small cell lung cancer
Dr. Jonathan Cheng discusses the approval of KEYTRUDA as monotherapy for patients with metastatic small cell lung cancer.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Cancer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Cancer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Cancer?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Jon Cheng, M.D., is a Vice President and Oncology Therapeutic Area Head at Merck Research Laboratories (MRL). He leads the Late Stage Clinical Development at Merck Oncology, and in this role oversees the clinical development of all late-stage clinical assets including pembrolizumab and its combinations as well as lenvatinib in multiple solid organ tumors including lung, head/neck, gastrointestinal, breast, gyn, and hematologic malignancies.
Dr. Cheng joined Merck in 2008 where he had previous responsibilities developing novel combinations within the Merck pipeline, incorporating biomarkers and companion diagnostic development into clinical trials, and directed a number of pembrolizumab registrational activities including supervising the approval of pembrolizumab in multiple tumors.
Prior to joining Merck, Dr. Cheng was an Associate Professor at Fox Chase Cancer Center where he was an attending physician for 11 years in the Department of Medical Oncology and continues to see patients as an Adjunct Professor. Dr. Cheng earned his M.D. degree from the University of Minnesota where he also completed his residency in Internal Medicine and completed his fellowship in Hematology-Oncology at Roswell Park Cancer Center. Dr. Cheng has published over 70 manuscripts and multiple book chapters and abstracts.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
